Ann: Entitlement Offer to raise up to $9.9 million, page-162

Gekko, thank you for sharing your perspective, which raises valid concerns about the company's history and current standing.

Indeed, a track record of lengthy time-to-market, limited sales, and shareholder value erosion could unsettle any investor. You're right; past performance has been far from rewarding, and the lack of communication or apparent progress can be upsetting.

However, it's also worth considering that the biotech sector is inherently high-risk and long-term, often requiring many years of R&D, regulatory approvals, and clinical trials before a company can generate sustainable revenue.

Furthermore, gaining approval from a body like the GBA for clinical trials could signify a turning point, marking the company's transition from a research-focused to a commercial stage.

It's essential to be cautious, and your concerns are a critical part of the broader investment discussion. However, for those who believe in the company's technology and its potential impact on patient care, such turning points could offer a new opportunity, despite the checkered past.

As always, due diligence and risk assessment are key when considering any investment.